A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies

Overview of attention for article published in Blood, August 2011

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 0 followers.

RT @Transplant_Doc: imatinib (Gleevec) is associated with 40% response rate in chronic graft vs. host disease http://t.co/kONA3IfR

RT @JSupportOncol: RT @transplant_doc: imatinib (Gleevec) is associated with 40% response rate in chronic graft vs. host disease http://t.co/Rj7Dmr14

RT @transplant_doc: imatinib (Gleevec) is associated with 40% response rate in chronic graft vs. host disease http://t.co/Rj7Dmr14

imatinib (Gleevec) is associated with 40% response rate in chronic graft vs. host disease http://t.co/kONA3IfR

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.